STOCKS TELEGRAPH

Tag: SLRX stock

  • Salarius Pharmaceuticals Inc. (SLRX) Rebounds After Hours Following its Recent Downfall

    On March 15, Salarius Pharmaceuticals Inc. (SLRX) finally rebounded in the after-hours following its continued downfall after its latest earnings. The company had declared its 2021 financial results on March 10.

    Source: iStock

    During the regular trading session, the stock suffered a loss of 7.00% while the volume of shares exchanged remained above the average. The stock closed the session in the red at a price of $0.3441 per share. Following this, the stock rebounded in the after-hours to add a good 10.43%. Hence, SLRX stock was trading at a value of $0.3800 per share in the after-hours on Tuesday.

    The clinical-stage oncology company, Salarius Pharmaceuticals Inc. is based in Houston, TX. Currently, its 45.21 million outstanding shares trade at a market capitalization of $16.73 million.

    What Happened with SLRX?

    On March 10, the company reported its financial results for the fourth quarter and full-year 2021. Following this, the stock entered a downtrend which continued till March 15’s regular session. After plunging down for over 10.39% in the past five days, the stock finally rebounded and entered green in the after-hours on Tuesday. Since there is no recent news from the company, the downfall seems to be the reason for the comeback. In addition to external factors, it seems the low price was taken as a good buying opportunity by the investors.

    Presently, SLRX stock stands at a year-to-date loss of 30.57% while it subtracted a huge value of 77.06% in the past year.

    2021 Financial Results

    For Q4 2021, the company reported a net loss of 44.1 million against $1.8 million in the year-ago period. Therefore, the net loss per basic and diluted share was $0.09 and $0.10 in Q4 2021 and 2020, respectively.

    Moreover, the fiscal 2021 net loss was $12.8 million against $7.4 million for fiscal 2020. Thus, the net loss per basic and diluted share was $0.31 and $0.50 for fiscal 2021 and 2020, respectively.

    Furthermore, SLRX ended 2021 with cash, cash equivalents, and restricted cash of $29.2 million. This compares to $11.1 million at the end of fiscal 2020. The company expects the cash position to be enough to fund its operations through 2023.

    SLRX’s Recent Participations

    Recently, the company participated in the Diamond Equity Research Emerging Growth Invitational 2022 Virtual Conference. SLRX’s CEO David Arthur, presented at the conference on February 24, 2022.

    Previously, Mr. Arthur also presented at the 2022 BIO CEO & Investor Conference which took place from February 14-17, 2022.

  • Salarius Pharmaceuticals, Inc. (SLRX) Stock Rebounds Aftermarket, Here’s What’s Happening.

    Salarius Pharmaceuticals, Inc. (SLRX) Stock Rebounds Aftermarket, Here’s What’s Happening.

    Salarius Pharmaceuticals, Inc. (SLRX) is a leading late-stage biotherapeutics firm engaged in developing cancer therapeutics for oncology patients. The lead pipeline candidate of the company is Seclidemstat in Phase 1/2 clinical-stage used for treating prostate, breast, ovary cancer, and tumors.

    The price of SLRX stock during the regular trading of March 9, 2022, was $0.37 with a decline of 2.40%. At the last check of the aftermarket, the stock rebounded by 13.3%.

    SLRX: Events and Happenings

    On March 03, 2022, SLRX updated that it will release its financials for the three months ended December 31, 2021, on March 10, 2022. The company will also host a conference call and webcast to discuss its corporate matters. On February 17, 2022, SLRX reported its Executive management’s participation at the Virtual Diamond Equity Research Emerging Growth Invitational 2022 Conference on February 24.

    On February 08, 2022, SLRX announced its CEO’s virtual presence at the 2022 BIO CEO & Investor Conference held on February 14-17. On January 13, 2022, SLRX informed the press about its entry into a definitive contract with DeuteRx, LLC for the acquisition of a small molecule targeted protein degradation platform or SP-3164. On December 29, 2021, SLRX reported the achievement of a dosing milestone in seclidemstat Phase 1/2 trials. The company assessed its efficacy against Ewing sarcoma and FET-rearranged sarcomas and advanced to the second lead-in safety unit.

    SLRX: Key Financials

    On November 04, 2021, SLRX released its unaudited financial report for the third quarter of fiscal 2021 ended September 30, 2021. Some of the key updates are as follows.

    Revenue

    No revenue was recorded by the company for Q3 2021, while a grant revenue of $1.37 million was reported during the same period of 2020.

    EPS

    Net loss per share basic and diluted in the third quarter of 2021 was $3.7 million, or $0.08 compared to $1.7 million, or $0.10 in the corresponding quarter of 2020. The company experienced a substantial incline in its earnings per share over the year.

    Conclusion

    SLRX stock price dipped 74% in the last year as the restrictions were imposed globally during the pandemic. The company’s stock rebounded in aftermarket trading as it is gearing for the fourth quarter financial statement release. The revenue guidance provided by the company for the quarter is $325 thousand against -$0.08 EPS.

  • Salaruis Pharmaceuticals Inc. (SLRX) stock’s Bullish Momentum Escalated After Hours. Why?

    Salaruis Pharmaceuticals Inc. (SLRX) stock’s Bullish Momentum Escalated After Hours. Why?

    On February 25, Salaruis Pharmaceuticals Inc. (SLRX) stock’s bullish momentum escalated in the after-hours as it added a further 10.03%. It seems investors are buying the stock due to its price’s downfall recently.

    During the regular session, the stock added 3.33% at its closing price of $0.3999 per share. The stock traded at a mild volume of just 18% of its 65-day average at 67.08K shares during the regular trading session. Still being quite near the recent 52-week low of $0.3507, SLRX stock continued gaining in the after-hours but with increased momentum. The stock reached a value of $0.4400 in the after-hours on Friday as it added a further $0.04 or 10.03%.

    The clinical-stage oncology company, Salaruis Pharmaceuticals Inc. has a market capitalization of $18.08 million. Currently, the company has 45.21 million shares outstanding in the market.

    What is Happening with SLRX?

    As most of the stock plunged down to new lows in recent days, SLRX also reached its 52-week low of $0.3510 on Thursday. The stock closed the session just above the new low at $0.3870. Thus, leading the way for investors to buy the stock in order to take advantage of the low price. Therefore, the stock entered an uptrend in the following sessions on Friday. While the regular trading saw a mild volume with a normal gain, things changed in the after-hours session as it gained momentum.

    The overall analysis of the stock movement shows a loss of 6.91% in the past five days alone. While the stock stands at a year-to-date loss of 19.31% it subtracted a value of 77.78% last year.

    Company News

    On February 24, the company’s CEO, David Arthur presented at the Diamond Equity Research Emerging Growth Invitational 2022 Virtual Conference.

    On February 22, the company filed a report on Form S-8, Securities to be offered to employees in employee benefit plans.

    Before that, SLRX’s CEO also presented at the 2022 BIO CEO & Investor Conference which took place from February 14 to 17, 2022.

    SLRX’s Financial Highlights

    In the third quarter of 2021, the company had a net loss of $3.7 million, against $1.7 mullion in the year-ago period. Resultantly, the net loss per basic and diluted share was $0.08 and $0.10 in Q3 of 2021 and 2020, respectively.

    Furthermore, as of September 30, 2021, the total working capital of the company was $33.6 million.

  • Dosing Milestone in Phase ½ Sarcoma Trial: Salarius Pharmaceuticals, Inc. (SLRX) Bullish After Hours

    Dosing Milestone in Phase ½ Sarcoma Trial: Salarius Pharmaceuticals, Inc. (SLRX) Bullish After Hours

    Salarius Pharmaceuticals, Inc. (SLRX) stock rebounded in the after-hours on the news of dosing milestone achievement in its ongoing trial. On December 29, the company announced achieving doing milestone in its Phase ½ Sarcoma Trial.

    During the regular session, the stock was in the red with a loss of 6.19% at its closing price of $0.4925. Following the news, the stock became bullish in the after-hours, reaching $0.5200 with a 5.58% gain.

    Currently, SLRX’s 44.78 million outstanding shares trade at a market capitalization of $23.51 million.

    Phase ½ Sarcoma Trial

    The company is conducting Phase ½ Sarcoma clinical trial for the evaluation of seclidemstat. Moreover, scelidemstat is under evaluation as a treatment for Ewing sarcoma and other FET-rearranged sarcomas. As per the recent announcement, the trial’s Ewing sarcoma patient arm has reached its second lead-in safety cohort. Moreover, this cohort would be treating the patients with seclidemstat 900 mg BID in combination with topotecan and cyclophosphamide.

    Seclidemstat is a reversible inhibitor of the LSD1 enzyme that is known to have an important role in the development as well as the progression of some cancers.

    In addition, the company expects potential data readouts from the trial in 2022, as enrollment continues in all patient groups. Currently, patient enrollment is happening across the U.S. at 13 clinical trial sites.

    SLRX’s Recent Developments

    Recently, the company participated in two conferences in the month of December.

    Firstly, SLRX’s CEO David Arthur presented at the Life Science Investor Forum which took place on December 16, 2021. Mr. Arthur shared an overview of the company’s achievements and upcoming milestones at the conference. Moreover, he also discussed the ongoing Phase ½ Sarcoma clinical trial of scelidemstat.

    Secondly, Mr. Arthur along with other members of SLRX participated in the Benchmark Company Discovery One-On-One Investor Conference. Moreover, this conference was held virtually on Thursday, December 2, 2021. Mr. Arthur and the management team hosted one-on-one meetings with the registered investors at the conference.

    SLRX’s Financials

    On November 04, the company declared its financial results for the third quarter of 2021.

    SLRX incurred a net loss per basic and diluted share of $0.08 (total net loss $3.7 million) in the third quarter of 2021. This compares to $0.10 (total net loss of $1.7 million) in the third quarter of 2020.

    Moreover, the company ended the third quarter with a working capital of $33.6 million on September 30, 2021.

  • What changed for these 49 stocks in Pre Market Session

    What changed for these 49 stocks in Pre Market Session

    Lizhi Inc. (LIZI) stock plunged -8.14% to $4.4 in the pre-market trading after reporting that it entered in-car audio collaboration with Xpeng Motors. The most recent rating by Citigroup, on February 18, 2020, is a Buy.
    American Airlines Group Inc. (NASDAQ: AAL) shares are trading up 4.72% at $16.85 at the time of writing. Company’s 52-week ranged between $8.25 to $30.78.
    FuelCell Energy Inc. (FCEL) is up more than 5.01% at $7.75 in pre-market hours Friday December 04, 2020. The firm recently declared the pricing of its underwritten public offering of 34,518,539 shares of its common stock, at a public offering price of $6.50 per share. The stock had jumped over 1.93% to $7.38 in the last trading session.
    Before the trading started on December 04, 2020, AMC Entertainment Holdings Inc. (AMC) is up 5.51% to reach $3.83. It has been trading in a 52-week range of $1.95 to $8.78.
    Cinemark Holdings Inc. (CNK) stock soared 6.02% to $14.1 in the pre-market trading. The most recent rating by Loop Capital, on November 19, 2020, is a Hold.
    Iterum Therapeutics plc (ITRM), a Biotechnology company, dropped about -3.8% at $0.809 in pre-market trading Friday.
    Norwegian Cruise Line Holdings Ltd. (NYSE: NCLH) shares are trading up 3.7% at $26.36 at the time of writing following its announcement extension of suspension of voyages. Company’s 52-week ranged between $7.03 to $59.78. Analysts have a consensus price target of $26.
    Before the trading started on December 04, 2020, Jaguar Health Inc. (JAGX) is up 7.84% to reach $0.399. It has been trading in a 52-week range of $0.19 to $1.08.
    Transocean Ltd. (RIG), a Oil & Gas Drilling company, rose about 4.43% at $2.12 in pre-market trading Friday after declaring amendments to certain financing documents and internal reorganization transactions to resolve allegations contained in purported notices of default.
    Novan Inc. (NOVN) stock soared 19.92% to $0.67 in the pre-market trading. The most recent rating by Piper Jaffray, on January 06, 2020, is a Neutral.
    Li Auto Inc. (LI) lost over -2.48% at $31.51 in pre-market trading Friday December 04, 2020 following declaration its pricing of follow-on public offering of American depositary shares.
    Southwestern Energy Company (NYSE: SWN) shares are trading up 2.13% at $2.88 at the time of writing. Company’s 52-week ranged between $1.06 to $3.90. Analysts have a consensus price target of $2.40.
    Occidental Petroleum (OXY) is up more than 3.23% at $16.92 in pre-market hours Friday December 04, 2020. The company recently reported the release of its 2020 Climate Report, which provides a pathway detailing milestones to achieve its net-zero aspirations. The stock had jumped over 3.15% to $16.39 in the last trading session.
    Torchlight Energy Resources Inc. (TRCH) is up more than 6.9% at $0.48 in pre-market hours Friday December 04, 2020. The stock had jumped over 15.13% to $0.45 in the last trading session.
    TransGlobe Energy (TGA) grew over 2.82% at $0.659 in pre-market trading today following its agreement to merge, extend and modernize its eastern Desert concessions.
    Before the trading started on December 04, 2020, Catabasis Pharmaceuticals Inc. (CATB) is up 2.07% to reach $1.97. It has been trading in a 52-week range of $1.25 to $8.59.
    Inovio Pharmaceuticals Inc. (INO) stock moved up 8.07 percent to $13.53 in the pre-market trading after declaring the execution of an agreement with Kaneka Eurogentec S.A., for Eurogentec to manufacture INOVIO’s COVID-19 vaccine candidate INO-4800 at their industry-leading GMP plasmid production scales.
    Clovis Oncology Inc. (CLVS) is down more than -4.81% at $5.15 in pre-market hours Friday December 04, 2020. The stock had jumped over 11.09% to $5.41 in the last trading session.
    Cinedigm Corp. (CIDM) gained over 71.43% at $0.96 in pre-market trading Friday December 04, 2020 after reporting that its eight additional linear streaming channels are now Available on Rad’s fast-growing global streaming platform.
    Onconova Therapeutics Inc. (ONTX) stock plunged -1.9% to $0.3143 in the pre-market trading. The most recent rating by H.C. Wainwright, on March 01, 2018, is a Buy.
    Marvell Technology Group Ltd. (MRVL) stock plunged -5.1% to $43.2 in the pre-market trading after announcing a quarterly dividend of $0.06 per share of common stock payable on January 14, 2021 to shareholders of record as of December 23, 2020. The most recent rating by Craig Hallum, on October 30, 2020, is a Buy.
    QEP Resources Inc. (QEP) stock soared 5.0% to $2.1 in the pre-market trading. The most recent rating by JP Morgan, on July 20, 2020, is a Neutral.
    Arlo Technologies Inc. (NYSE: ARLO) shares are trading up 3.09% at $7.0 at the time of writing. The company recently revealed that Matthew McRae, CEO, and Gordon Mattingly, CFO, will present at the Raymond James Virtual Technology Investors Conference on Tuesday, December 8, 2020. Company’s 52-week ranged between $1.20 to $7.75. Analysts have a consensus price target of $6.
    Before the trading started on December 04, 2020, Nxt-ID Inc. (NXTD) is down -3.91% to reach $0.41. It has been trading in a 52-week range of $0.21 to $0.89.
    Halliburton Company (HAL) gained over 3.66% at $18.68 in pre-market trading Friday December 04, 2020 following its deal with Accenture (ACN), to accelerate Halliburton’s digital supply chain transformation and support digitalization within the Company’s manufacturing function.
    United Microelectronics (UMC) stock soared 10.32% to $8.55 in the pre-market trading. The most recent rating by Credit Suisse, on October 12, 2020, is an Outperform.
    Before the trading started on December 04, 2020, Cloudera Inc. (CLDR) is up 14.85% to reach $13.3 after reporting results for its third quarter of fiscal 2021, ended October 31, 2020. It has been trading in a 52-week range of $4.76 to $14.20.
    Before the trading started on December 04, 2020, Isoray Inc. (ISR) is down -4.92% to reach $0.47. It has been trading in a 52-week range of $0.35 to $1.06.
    iBio Inc. (AMEX: IBIO) shares are trading down -0.66% at $1.51 at the time of writing. The firm recently reported an agreement with Belgium-based ATB Therapeutics to produce its bioengineered antibody-toxin fusion proteins using iBio’s FastPharming® System. Company’s 52-week ranged between $0.14 to $7.45. Analysts have a consensus price target of $2.55.
    Centennial Resource Development Inc. (CDEV) stock soared 3.13% to $1.32 in the pre-market trading. The most recent rating by MKM Partners, on November 30, 2020, is a Neutral.
    BioCryst Pharmaceuticals Inc. (BCRX) is up more than 24.44% at $6.39 in pre-market hours Friday December 04, 2020 following the FDA Approval of ORLADEYO™ (berotralstat), First Oral, Once-daily Therapy to prevent attacks in Hereditary Angioedema patients. The stock had jumped over 1.88% to $5.14 in the last trading session.
    Borr Drilling Limited (BORR) is up more than 6.86% at $0.854 in pre-market hours Friday December 04, 2020. The stock had dropped over -1.78% to $0.80 in the last trading session.
    Before the trading started on December 04, 2020, Blink Charging Co. (BLNK) is up 4.14% to reach $23.64 after declaring an agreement with JSC Management Group, a large Burger King franchisee, to deploy numerous EV charging stations at key Burger King locations across the Northeast. It has been trading in a 52-week range of $1.25 to $34.67.
    Banco Santander S.A. (SAN) grew over 3.74% at $3.33 in pre-market trading today.
    Kandi Technologies Group Inc. (NASDAQ: KNDI) shares are trading up 2.98% at $8.3 at the time of writing. Company’s 52-week ranged between $2.17 to $17.45.
    InVivo Therapeutics Holdings Corp. (NVIV) lost over -4.67% at $0.6101 in pre-market trading Friday December 04, 2020.
    Aehr Test Systems (AEHR), a Semiconductor Equipment & Materials company, dropped about -8.74% at $1.88 in pre-market trading Friday after receiving $4.3 million order for initial FOX-XP™ test cell for production test of mobile sensor devices.
    ICICI Bank Limited (IBN) grew over 4.48% at $13.75 in pre-market trading today.
    NanoVibronix Inc. (NAOV) stock moved down -7.96 percent to $1.04 in the pre-market trading following the announcement of $6.0 million private placement.
    DocuSign Inc. (DOCU), a Software – Application company, rose about 4.43% at $241.25 in pre-market trading Friday.
    Dada Nexus Limited (DADA) is up more than 4.4% at $47.2 in pre-market hours Friday December 04, 2020 after reporting that Dada Now has partnered with dozens of cake chain brands across China, doubling the number of cooperating stores year-over-year as of November 2020. The stock had dropped over -15.65% to $45.21 in the last trading session.
    Salarius Pharmaceuticals Inc. (SLRX) stock moved up 1.85 percent to $1.1 in the pre-market trading.
    Auris Medical Holding Ltd. (NASDAQ: EARS) shares are trading down -3.23% at $3.3 at the time of writing after it pricing $8,000,000 common shares offering priced at-the-market. Company’s 52-week ranged between $0.65 to $6.60. Analysts have a consensus price target of $2.50.
    Acasti Pharma Inc. (ACST) lost over -2.94% at $0.33 in pre-market trading Friday December 04, 2020.
    Micro Focus International plc (MFGP) is up more than 6.3% at $6.07 in pre-market hours Friday December 04, 2020. The firm recently declared the findings of its ‘Endless Modernization’ research with Standish Group. The stock had jumped over 14.66% to $5.71 in the last trading session.
    BP p.l.c. (BP), a Oil & Gas Integrated company, rose about 4.54% at $22.33 in pre-market trading Friday.
    Tantech Holdings Ltd (NASDAQ: TANH) shares are trading up 4.27% at $1.71 at the time of writing after announcing the launch by its subsidiary, Shangchi Automobile Co., Ltd. (“Shangchi Automobile”), of its newest highly innovative driverless and autonomous street sweeper. Company’s 52-week ranged between $0.81 to $3.65.
    Trine Acquisition Corp. (TRNE) gained over 7.05% at $15.49 in pre-market trading Friday December 04, 2020.
    Enlivex Therapeutics Ltd. (ENLV) grew over 5.26% at $12.0 in pre-market trading today after reporting positive interim results of an investigator-initiated Phase II clinical trial evaluating AllocetraTM in severe and critical COVID-19 patients.